Condition: Head Neck Cancer · Squamous Cell Cancer of Head and Neck (SCCHN) · Cancer Pain · Sponsor: University of Virginia
This phase 1 multi-site study investigates the safety and initial effectiveness of focused ultrasound lesioning of the contralateral mesencephalon for severe, opioid-resistant pain associated with head and neck cancer and brachial cancer.
This description comes directly from the study's public registry record.
William J Elias, MD · 434-924-0451 · wje4r@uvahealth.org
Marian Abdelmalek, MS · 434-924-8827 · mka6s@uvahealth.org
Always discuss trial participation with your own doctor first.
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Weill Cornell Medicine | New York, New York, United States | Not Yet Recruiting |
| Oregon Health and Science University | Portland, Oregon, United States | Not Yet Recruiting |
| The University of Texas Southwestern Medical Center | Dallas, Texas, United States | Not Yet Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Not Yet Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07405645